Home Research
Research


Biomarker Development for Clinical Diagnosis of Disease Stage and response to Treatment in IBD PDF Print E-mail

This research study aims to identify biomakers (proteins in the blood) that would help to diagnose Inflammatory Bowel Disease (IBD) and to help determine the severity of the disease. This study is being conducted at British Columbia’s Children Hospital by Dr. Kevan Jacobson, who has received funding from the Genome BC CDRD Development Fund.

IBD is a group of chronic intestinal (gut) diseases (it does not go away nor does it have a cure at present) characterized by inflammation (irritation) in the bowel. The most common types of IBD are Ulcerative Colitis and Crohn's Disease. 

Currently IBD is diagnosed using a number of tests: blood tests, colonoscopy (using a flexible tube to see the inside of you gut), biopsies (the removal of a tiny sample of your gut to examine in the lab), MRI (scan of the body), x-rays or ultrasound (another way of seeing inside of the body), and reviewing the medical history. 

A biomarker is a term often used to refer to a protein measured in the blood whose concentration can show if a disease is present and how severe it is. Disease related biomarkers help to show where there is a threat of disease, if a disease already exists, or how such a disease may develop in an individual case.   

The purpose of this pilot study is to identify a reliable biomarker test to help in diagnosing and prediction of the severity of IBD that could ultimately lead to future treatments of IBD. This study will test for different biomarkers using techniques called quantitative mass spectrometry and HPLC which can identify the composition of biomarkers.

A total of 80 children 7-17 years of age, who have been recently diagnosed with IBD not yet started on therapy or within the first 2 weeks of initiation of a 5-ASA compound, will be recruited to the study.

If you agree to take part in this study you will  be asked about your health history and have one blood sample (6.5mL or about 1.5 teaspoons) taken to test for biomarkers. You may have pain or bruising at the site where the blood will be drawn. Your doctor can put some cream on your arm to stop the discomfort where the needle is inserted. There are no direct benefits from being in this study. Your involvement is voluntary; the study will not cost you anything. For more information about this study, please contact: 

Terry Viczko, RN
Research Coordinator
Division of Gastroenterology, BC Children's Hospital
Phone: 604-875-2345 ext. 5312
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it   

 
Humira (Adalimumab) Clinical Trial PDF Print E-mail

Abbott Laboratories – A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Paediatric Subjects with Moderate to Severe Crohn’s Disease

The purpose of this study is to evaluate the safety, efficacy and dosing of Adalimumab for the treatment of moderate to severe Crohn’s disease in paediatric subjects.  While Adalimumab is approved for the treatment of adult Crohn’s disease in the United States, European Union and Canada, it is still being tested for use in paediatrics.

This study is being conducted at about 55 treatment centers in the United States, Canada and Europe. Approximately 184 paediatric subjects with Crohn’s disease will participate in this study for up to 12 months and 13 weeks.

A naturally occurring substance in our immune system called the tumor necrosis factor-alpha (TNFα) is thought to play a role in creating the chronic inflammation that causes the symptoms of Crohn’s disease. Adalimumab is an antibody that has been developed to relieve the symptoms of Crohn’s disease by attaching to TNFα and thus helping control the inflammation. An antibody is a naturally occurring substance produced by the immune system. Adalimumab is made in a laboratory and is identical to a natural human antibody.

Please contact your Gastroenterologist or the research coordinator for more information:

Terry Viczko, RN
Research Coordinator
Division of Gastroenterology, BC Children's Hospital
Phone: 604-875-2345 ext. 5312
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 
Michael J. Howorth IBD Genetic, Environmental, and Microbial (GEM) Project PDF Print E-mail

Michael J. Howorth Inflammatory Bowel Disease (IBD) Genetic, Environmental, and Microbial (GEM) ProjectThe GEM Project, funded by a $5-million grant from the Crohn’s and Colitis Foundation of Canada, is a nation-wide clinical study attempting to identify the causes of Crohn’s disease. The study is recruiting 5000 full biological siblings of patients with Crohn’s disease to answer questions about their diet and environment and provide a blood sample, a stool sample, and a urine sample. Siblings must be between 6 and 35 years old and must not have inflammatory bowel disease, celiac disease or diabetes.

The results will provide important information about the causes of Crohn's disease which may lead to the development of new and better therapies or possibly a cure.

Please contact the Research Coordinator for more information:

Terry Viczko, RN

Research Coordinator

Division of Gastroenterology, BC Children's Hospital

Phone: 604-875-2345 ext. 5312

Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it  

 
 
The Therapeutic Potential of the Human Gut Metabolome and Luminal Host Factors Against Enteric Infection PDF Print E-mail

As the name suggests, the purpose of this study is to determine the therapeutic potential of the human gut metabolome and luminal host factors against enteric infection. In other words, this study aims to collect stool samples to study the role of molecules from the human gut and to find out if they can help fight against intestinal infections. In this small pilot study we will look at proteins and small molecules found in stool samples to establish if they act on pathogens (foreign matter that can harm the body) entering the gut and if they help to protect the gut.

You can participate in this study by providing a stool specimen if you are able to collect a stool sample and able to provide informed consent. You should not experience any harm or side effects from providing a stool sample.

For more information about this study, contact the research Coodinator at BC Children's:

Terry Viczko
Research Coordinator
Email: 
This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Phone: 604-875-2345 Ext. 5312
Fax: 604-875-3244 Attn: Terry Viczko